Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH.

Value Health. 2013 Sep-Oct;16(6):973-86. doi: 10.1016/j.jval.2013.07.006.

PMID:
24041347
[PubMed - indexed for MEDLINE]
2.

The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer.

Malik T, Reimer J, Gumel A, Elbasha EH, Mahmud S.

Math Biosci Eng. 2013 Aug 1;10(4):1173-205. doi: 10.3934/mbe.2013.10.1173.

PMID:
23906207
[PubMed - indexed for MEDLINE]
3.

Model for hepatitis C virus transmissions.

Elbasha EH.

Math Biosci Eng. 2013 Aug 1;10(4):1045-65. doi: 10.3934/mbe.2013.10.1045.

PMID:
23906202
[PubMed - indexed for MEDLINE]
4.

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.

Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH.

BMC Infect Dis. 2013 Apr 27;13(1):190. [Epub ahead of print]

PMID:
23621902
[PubMed - as supplied by publisher]
Free PMC Article
5.

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.

Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.

Appl Health Econ Health Policy. 2013 Feb;11(1):65-78. doi: 10.1007/s40258-012-0007-8.

PMID:
23355388
[PubMed - indexed for MEDLINE]
6.

Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R.

Hepatology. 2013 Jun;57(6):2164-70. doi: 10.1002/hep.26218. Epub 2013 May 6.

PMID:
23280550
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Cost-effectiveness of raltegravir in HIV/AIDS.

Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):627-39. doi: 10.1586/erp.11.79. Review.

PMID:
22098278
[PubMed - indexed for MEDLINE]
8.

Prevalence of antibodies associated with herd immunity: a comment.

Elbasha EH.

Med Decis Making. 2011 May-Jun;31(3):511-3; author reply 514-5. doi: 10.1177/0272989X11398667. No abstract available.

PMID:
21610260
[PubMed - indexed for MEDLINE]
9.

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.

Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R.

BMC Med. 2011 May 12;9:54. doi: 10.1186/1741-7015-9-54.

PMID:
21569406
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Muñoz N, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96. doi: 10.1158/1055-9965.EPI-10-0791.

PMID:
21300618
[PubMed - indexed for MEDLINE]
Free Article
11.

Impact of vaccinating boys and men against HPV in the United States.

Elbasha EH, Dasbach EJ.

Vaccine. 2010 Oct 4;28(42):6858-67. doi: 10.1016/j.vaccine.2010.08.030. Epub 2010 Aug 14.

PMID:
20713101
[PubMed - indexed for MEDLINE]
12.

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235.

PMID:
20530494
[PubMed - indexed for MEDLINE]
Free Article
13.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, Opravil M.

HIV Clin Trials. 2009 Jul-Aug;10(4):233-53. doi: 10.1310/hct1004-233.

PMID:
19723611
[PubMed - indexed for MEDLINE]
15.
16.

Economics of stockpiling for an influenza pandemic.

Dhankhar P, Dasbach EJ, Elbasha EH.

Lancet Infect Dis. 2009 Aug;9(8):459-60. doi: 10.1016/S1473-3099(09)70183-5. No abstract available.

PMID:
19628168
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.

Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E.

AIDS Res Hum Retroviruses. 2009 Jul;25(7):679-89. doi: 10.1089/aid.2008.0254.

PMID:
19552590
[PubMed - indexed for MEDLINE]
18.

Age-based programs for vaccination against HPV.

Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E.

Value Health. 2009 Jul-Aug;12(5):697-707. doi: 10.1111/j.1524-4733.2009.00512.x.

PMID:
19490561
[PubMed - indexed for MEDLINE]
19.

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.

Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):459-66.

PMID:
18990021
[PubMed - indexed for MEDLINE]
Free Article
20.

A multi-type HPV transmission model.

Elbasha EH, Dasbach EJ, Insinga RP.

Bull Math Biol. 2008 Nov;70(8):2126-76. doi: 10.1007/s11538-008-9338-x. Epub 2008 Oct 8.

PMID:
18841421
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk